medline.ch Onkologie Urologische Tumoren

	Pulmonary Metastases From Undiagnosed Prostate Cancer Mimicking Late Recurrence of Renal Cell Carcinoma: Diagnosis Confirmed by Thoracoscopic Biopsy. Cureus Tsuiki S, Oki T, Iizuka S, Otsuki Y, Nakamura T. PMID: 41873254 [PubMed]
	The Impact of the Relevant Factors as High-Complexity Tumors in Robot-Assisted Partial Nephrectomy. Int J Urol Teishima J, Hara T, Ueki H, Wakita N, Okamura Y, Bando Y, Suzuki K, Terakawa T, Chiba K, Yao A, Miyake H. PMID: 41873011 [PubMed - indexed for MEDLINE]
	Impact of PSMA PET on the management and clinical outcomes of patients with biochemical failure of prostate cancer after definitive treatment: a systematic review and meta-analysis. Int Urol Nephrol Zhu G, Xiong X, Peng Z, Zhu W, Huang W, Yang J, Wang S, Xu H, Yang L. PMID: 41872648 [PubMed - as supplied by publisher]
	Comparison of [(18)F]FDG and [(18)F]PSMA-1007 PET/CT in the Evaluation of Muscle-Invasive Bladder Cancer: A Pilot Feasibility Study. Mol Imaging Biol Avilez ND, Tineo RN, Rodrigues JT, Ottaiano AD, Saito HPA, Amorim BJ, Carvalheira JBC, Reis LO, Ramos CD. PMID: 41872599 [PubMed - as supplied by publisher]
	Self-help cognitive behavioural therapy for hot flushes and night sweats during androgen deprivation therapy for prostate cancer: the MANCAN2 randomized controlled trial. Br J Cancer Crabb SJ, Morgan A, Stefanopoulou E, Fleure L, Griffiths GO, Boxall C, Wilding S, Nearchou T, Ewings S, Nuttall J, Eminton Z, Tilt E, Whitby E, Siu B, Ridley P, Robson L, Nobes J, Preece J, Bacon R, Martin J, Chamberlain S, Fenlon D, Hunter M, Richardson A. PMID: 41872531 [PubMed - as supplied by publisher]
	Risk factors for incidental prostate cancer following surgery for benign prostatic enlargement: A systematic review and meta-analysis. Prostate Cancer Prostatic Dis Cormio A, Matsukawa A, Dematteis A, Alfarhan AR, Miszczyk M, Roessler N, Alqahtani AS, Mancon S, Tsuboi I, Rajwa P, Falagario UG, Sanguedolce F, Busetto GM, Bettocchi C, Carrieri G, Cormio L, Galosi AB, D'Andrea D, Kimura T, Shariat SF. PMID: 41872314 [PubMed - as supplied by publisher]
	Patient-derived organoids in renal cell carcinoma: A review of methodologies and applications. Urol Oncol Gavi F, Pallotta G, Sighinolfi MC, Fettucciari D, Panio E, Assumma S, Russo P, Sanesi D, Silvestri A, Iacovelli R, Ciccarese C, Ragonese M, Foschi N, Totaro A, Bientinesi R, Bielli P, Nero C, Sette C, Rocco B. PMID: 41872011 [PubMed - as supplied by publisher]
	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma, version 3.0. J Immunother Cancer McKay RR, Ajmera A, Atkins MB, Barata PC, Bergerot C, Bukavina L, Choueiri TK, Desai A, Hakimi AA, Poteat S, Powles T, Rini BI, Shuch B, Signoretti S, Siva S, Xu W, Yip W, Zhang T, Pal SK. PMID: 41871874 [PubMed - indexed for MEDLINE]
	LM-UNet: Lightweight Mamba-UNet Prostate MRI image segmentation network. PLoS One Xu K, Zhou S, Chen Y, Chen J, Zhang N, Liao Y. PMID: 41871125 [PubMed - indexed for MEDLINE]
	Association of Prophylactic Intravenous Corticosteroid Premedication With Toxicity and Survival in Patients Receiving Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma. Int J Urol Shinohara M, Yamamoto H, Kawashima Y, Sekine Y, Narita S, Kobayashi S, Abe N, Kodama H, Fujita N, Okamoto T, Numakura K, Sato S, Habuchi T, Ohyama C, Hatakeyama S. PMID: 41870296 [PubMed - indexed for MEDLINE]
	Association between short-term radiation-induced toxicity and oncological outcomes in high-risk prostate cancer: a retrospective single-centre cohort study. Acta Oncol Kahlmeter Brandell J, Valachis A, Ugge H, Smith D, Johansson B. PMID: 41870228 [PubMed - indexed for MEDLINE]
	Patterns of Supplement Use in Prostate Cancer Survivors: A Cross-Sectional Survey. Ir Med J Shine C, Johnston KE, Cushen SJ. PMID: 41869938 [PubMed - indexed for MEDLINE]
	Investigation of non-visible haematuria in a tertiary urology service. Ir Med J O'Mahony CJ, Low E, Lynch OE, Daly K, D'Arcy F, Dowling C. PMID: 41869919 [PubMed - indexed for MEDLINE]
	Nanomedicine Targeting Cancer-Associated Fibroblasts in Prostate Cancer: From Biological Mechanisms to Integrated Theranostic Strategies. Int J Nanomedicine Qian F, Zhou J, Tang Y, Chen J, Zuo J, Gou K, Tan C, Fang J, Zhao Z, Zhao J, Wen L, Fu S, Yang J, Wang C, Zhang Z. PMID: 41869404 [PubMed - indexed for MEDLINE]
	Gold Nanoparticles in Bladder Cancer Applications: A Paradigm Shift from Diagnostic Tools to Integrated Theranostic Platforms. Int J Nanomedicine Zhang X, Wu X, Du J, Mei J, Chen F, Lou K. PMID: 41869400 [PubMed - indexed for MEDLINE]
	Cause-specific mortality beyond prostate cancer in young men: a population-based study of second malignancies and non-tumor causes. Am J Transl Res Kang Y, Liu J, Lin Y, Pang L. PMID: 41868909 [PubMed]
	Identification of risk factors for the development and prognosis of bone metastases in renal cell carcinoma: development and validation of a predictive model. Am J Cancer Res Zeng W, Wu Z, Sun Y, Ma M, Fan A, Liu Z, Luo S. PMID: 41868662 [PubMed]
	Phellinus linteus polysaccharides inhibit castration-resistant prostate cancer progression possibly via dual modulation of PIK3R1 and PGC-1Î±: a preclinical evaluation. Am J Cancer Res Wei W, Huang J, Xie L, Xu Z, Lin C, Chen M. PMID: 41868659 [PubMed]
	Diagnostic Value of Multiparametric Transrectal Ultrasound in Patients with Suspected Carcinoma of Prostate: A Tertiary Care Centre Experience. Indian J Radiol Imaging Chowhan PS, Gorsi U, Mavuduru R, Lal A, Mete UK, Kakkar N. PMID: 41867289 [PubMed]
	Diagnosis of penile cancer with ex vivo fluorescence confocal microscopy using the HistologÂ® Scanner. BJU Int Zhang X, Almeida-Magana R, Mendes LST, Lavergne DF, Alnajjar H, Shaw G, Freeman A, Muneer A, Haider A. PMID: 41867020 [PubMed - as supplied by publisher]

Artikel 1 - 20 / 176991

Seite 1 von 8850

Suchbegriffe

Benutzen Sie englische Suchbegriffe für Ihre Suche in medline.ch.

Übersetzungsproblem?

mehr >>



		Zeitfenster

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Datenschutzerklärung / Privacy Policy \| Werbung